Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Christopher Torrance"'
Autor:
Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0206729 (2018)
[This corrects the article DOI: 10.1371/journal.pone.0176578.].
Externí odkaz:
https://doaj.org/article/3b1d46dd2e1c44bd9192e6b3659faaed
Autor:
Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth
Publikováno v:
PLoS ONE, Vol 12, Iss 4, p e0176578 (2017)
[This corrects the article DOI: 10.1371/journal.pone.0149099.].
Externí odkaz:
https://doaj.org/article/51dcef158365434191781921fad1b8e1
Autor:
Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0154007 (2016)
Externí odkaz:
https://doaj.org/article/f368df72c76b4ff5b74680cc063e2e4a
Autor:
Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J Lord, Alan Ashworth
Publikováno v:
PLoS ONE, Vol 11, Iss 2, p e0149099 (2016)
Activating KRAS mutations are found in approximately 20% of human cancers but no RAS-directed therapies are currently available. Here we describe a novel, robust, KRAS synthetic lethal interaction with the cyclin dependent kinase, CDK1. This was disc
Externí odkaz:
https://doaj.org/article/a24d68f13ee747b2bd872f1e4562042f
Autor:
Jeffrey J Wallin, Jane Guan, Kyle A Edgar, Wei Zhou, Ross Francis, Anthony C Torres, Peter M Haverty, Jeffrey Eastham-Anderson, Sabrina Arena, Alberto Bardelli, Sue Griffin, John E Goodall, Kyla M Grimshaw, Klaus P Hoeflich, Christopher Torrance, Marcia Belvin, Lori S Friedman
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e36402 (2012)
The PTEN/PI3K pathway is commonly mutated in cancer and therefore represents an attractive target for therapeutic intervention. To investigate the primary phenotypes mediated by increased pathway signaling in a clean, patient-relevant context, an act
Externí odkaz:
https://doaj.org/article/64952bf9ee0a4f75af0606c666386285
Publikováno v:
Journal of International Business and Economics. 21:18-27
Autor:
Rachel Brough, Christopher J. Lord, Marieke Aarts, James Campbell, Asha Konde, Eliana Marinari, Jenna L. Riffell, Alberto Bardelli, Sara Costa-Cabral, Christopher Torrance, Alan Ashworth
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0154007 (2016)
PLoS ONE, Vol 12, Iss 4, p e0176578 (2017)
PLoS ONE, Vol 12, Iss 4, p e0176578 (2017)
There is an error in S1 Table. Columns were incorrectly labeled and the data in columns N and R were erroneously duplicated. Please see the corrected S1 Table here.
Autor:
Robert Lagier, Alice Wang, Sue Rigby, Christopher Torrance, John J. Sninsky, Shirley Kwok, Cindy Christopherson
Publikováno v:
Cancer Research. 70:P2-09
Background: Activation of signaling pathways, loss of tumor suppressors and oncogenic mutations often lead to dysregulation of glycolysis and tumorigenesis. We performed expression analysis on genetically-defined human isogenic breast cancer cell lin
Publikováno v:
BMC Research Notes
Background The epidermal growth factor receptor family is expressed in breast cancer, and agents targeting this pathway have single agent effects (e.g. traztuzumab). Development of resistance may be due to the presence of alternative pathways, partic
Autor:
Asha Konde, Alan Ashworth, Rachel Brough, Jenna L. Riffell, Christopher J. Lord, Eliana Marinari, James Campbell, Christopher Torrance, Marieke Aarts, Sara Costa-Cabral, Alberto Bardelli
Publikováno v:
Ashworth, Alan; Costa-Cabral, S; Brough, R; Konde, A; Aarts, M; Campbell, J; et al.(2016). CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/6q48j0gn
PLoS ONE
PLoS ONE, Vol 13, Iss 10, p e0206729 (2018)
PLoS ONE, Vol 11, Iss 2, p e0149099 (2016)
PLoS ONE
PLoS ONE, Vol 13, Iss 10, p e0206729 (2018)
PLoS ONE, Vol 11, Iss 2, p e0149099 (2016)
Activating KRAS mutations are found in approximately 20% of human cancers but no RAS-directed therapies are currently available. Here we describe a novel, robust, KRAS synthetic lethal interaction with the cyclin dependent kinase, CDK1. This was disc